Business Context and Reporting Period
Company: Cardio Diagnostics Holdings, Inc. (CDIO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Cardio Diagnostics is an emerging growth company developing AI-driven, epigenetic-based clinical blood tests for cardiovascular disease (CVD). Its primary commercial products are Epi+Gen CHD (three-year risk assessment) and PrecisionCHD (early detection of coronary heart disease). The company also launched HeartRisk, a SaaS risk intelligence platform, in February 2024. The company operates with a limited number of employees (15 total as of March 2025) and relies on third-party CLIA-certified laboratories for testing.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $34,890 | $17,065 |
| Net Loss | $(8,383,453) | $(8,376,834) |
| Operating Expenses | $8,400,767 | $7,259,524 |
| Cash and Cash Equivalents (Dec 31) | $7,827,487 | $1,283,523 |
| Accumulated Deficit | $(22,751,833) | $(14,368,380) |
| Net Cash Used in Operating Activities | $(4,993,104) | $(5,672,175) |
| Net Cash Provided by Financing Activities | $11,941,258 | $3,632,468 |
Note: The company has not generated significant revenue and has incurred operating losses since inception. Margins are not applicable due to nominal revenue and significant operating losses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 104% year-over-year, rising from $17,065 in 2023 to $34,890 in 2024, driven by expanded partnerships with provider organizations.
- Expense Increases: General and Administrative (G&A) expenses increased by approximately $1.23 million (18%) to $8.17 million, primarily due to a significant increase in stock-based compensation ($2.59 million in 2024 vs. $1.28 million in 2023) following new option grants in Q1 2024.
- R&D Decrease: Research and Development expenses decreased by $116,057 (80%) to $29,125, attributed to fewer laboratory runs for new product pipeline development in 2024 compared to 2023.
- Liquidity Improvement: Cash balances increased by $6.54 million to $7.83 million, largely funded by $12.55 million in proceeds from the sale of common stock and warrants (including an At-the-Market offering and a private placement).
- Other Income/Expense: The company reported a minor net expense of $(17,576) in 2024, a significant improvement from the $(1.13) million expense in 2023, which included a large non-cash change in fair value of derivative liability and interest expense related to convertible notes that were fully converted in 2023.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy:
- The company expects to continue incurring losses as it invests in sales, marketing, and product development.
- Strategy focuses on expanding adoption across health systems, self-insured employers, and leveraging newly awarded CPT PLA codes (0439U and 0440U).
- Management anticipates long sales and partnership cycles (up to 14 months).
- The company plans to establish an internal CLIA laboratory in 2025 to reduce costs, though timing may be delayed to preserve resources.
- Regulatory (FDA LDT Rule): A final FDA rule published in May 2024 subjects Laboratory-Developed Tests (LDTs) to medical device regulations, with phased implementation beginning May 6, 2025. This could substantially increase costs and regulatory burdens. Litigation challenging this rule is ongoing.
- Liquidity: The company requires additional capital to fund operations beyond the next 12 months. It relies on equity offerings (ATM and private placements) which may be dilutive.
- Nasdaq Compliance: The company received notice of non-compliance with the Nasdaq Minimum Bid Price Requirement ($1.00/share). It has been granted an extended compliance period until June 2, 2025, to regain compliance, potentially via a reverse stock split. Failure to comply could result in delisting.
- Reimbursement: The company currently lacks broad third-party payer coverage. Commercial success depends on securing reimbursement, which is uncertain and may take years.
- Intellectual Property: Core technology is licensed from the University of Iowa Research Foundation (UIRF). The license could be terminated for breach of obligations, and UIRF retains rights to grant non-exclusive licenses for certain technical information to third parties.
- Legal Proceedings: The company is not currently a party to material litigation. However, there are unresolved claims regarding placement agent fees (Boustead Securities, Benchmark Company, Northland Securities) which the company disputes or believes are moot. No lawsuits have been filed as of the report date.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.8 million cash balance against the burn rate (~$5 million operating cash outflow annually) and the timeline for the internal lab setup.
- Nasdaq Status: Monitor the company's progress toward regaining compliance with the $1.00 minimum bid price requirement by the June 2, 2025 deadline.
- FDA LDT Compliance: Assess the financial impact of the new FDA LDT regulations and the status of the ongoing litigation challenging the rule.
- Revenue Sustainability: Evaluate the scalability of revenue given the nominal base ($34,890) and the reliance on long sales cycles and future payer reimbursement.
- Dilution Risk: Review the terms of the At-the-Market (ATM) offering and outstanding warrants (8.5 million warrants) and options (3.6 million options) to understand potential dilution from future capital raises.
- IP License Terms: Confirm the stability of the exclusive license with UIRF and the potential for third-party competition via non-exclusive technical information licenses.